Diffusion Pharmaceuticals Inc (NASDAQ:DFFN)’s share price traded down 5.8% on Wednesday . The company traded as low as $0.46 and last traded at $0.49, 3,833,931 shares changed hands during trading. A decline of 25% from the average session volume of 5,136,733 shares. The stock had previously closed at $0.52.

A number of analysts have recently weighed in on the company. HC Wainwright dropped their price target on Diffusion Pharmaceuticals from $10.00 to $3.50 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. ValuEngine upgraded Diffusion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, December 11th.

The company has a current ratio of 5.52, a quick ratio of 5.52 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $16.91 million, a price-to-earnings ratio of -0.08 and a beta of -0.18. The firm has a 50-day moving average of $0.44 and a 200 day moving average of $1.43.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last posted its earnings results on Monday, November 11th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.11. Equities research analysts predict that Diffusion Pharmaceuticals Inc will post -1.25 EPS for the current fiscal year.

An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Wells Fargo & Company MN bought a new stake in Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 149,875 shares of the company’s stock, valued at approximately $427,000. Wells Fargo & Company MN owned 4.44% of Diffusion Pharmaceuticals at the end of the most recent reporting period. 2.02% of the stock is owned by institutional investors.

Diffusion Pharmaceuticals Company Profile (NASDAQ:DFFN)

Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.

See Also: Put Option

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.